Crossref
Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma
CA: A Cancer Journal for Clinicians · 2026-05 · 76 (3)
DOI: 10.3322/caac.70085 ↗Kurz gefasst
Fachartikel in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 22.06.2026. Verfasst von Carrie Printz.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Printz, C. (2026). Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma. CA: A Cancer Journal for Clinicians, 76(3). https://doi.org/10.3322/caac.70085
Vancouver
Printz C. Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma. CA: A Cancer Journal for Clinicians. 2026;76(3). doi:10.3322/caac.70085
BibTeX
@article{Printz2026,
author = {Printz, Carrie},
title = {Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma},
journal = {CA: A Cancer Journal for Clinicians},
year = {2026},
volume = {76},
number = {3},
doi = {10.3322/caac.70085}
}
EUVIMED